Colorectal Cancer Screening and Health Equity



In the United States, colorectal cancer (CRC) is the third leading cause of cancer-related deaths in men and in women, and the second most common cause of cancer deaths when men and women are combined.¹ Despite advancements in screening and treatment, colorectal cancer does not affect every community the same. New cases (incidence) and deaths (mortality) vary substantially by race, ethnicity, socioeconomic status, and geography. For example:

- The highest survival rates are for Asian American/Pacific Islanders (68%) and the lowest are for Blacks (60%) onequarter of whom are diagnosed with distant-stage disease.¹
- Mortality is 30-40% higher among residents of poor counties, in part due to differences in access to early detection and high-quality cancer treatment.²
- Incidence and mortality rates are highest in Appalachia and parts of the South and Midwest and lowest in the West and Northeast.¹

Death rates, 2015-2019 by race and ethnicity, for colorectum Non-Hispanic black Image: Image:

Average annual rate per 100,000, age adjusted to the 2000 US standard population. Data sources: National Center for Health Statistics (NCHS), Centers for Disease Control and Preventian, 2021

Although colorectal cancer is one of the few cancers that can be prevented through screening, heightened incidence and mortality among certain groups may, in part, be attributed to disparities in the screening process.

Most colorectal deaths in the U.S. are attributable to not getting screened.³ Screening rates are lowest among ages 50-54, Asian Americans, the uninsured, recent immigrants, and those with less than a high school diploma.² Barriers often cited in screening uptake are affordability, lack of a family history or symptoms, feelings of embarrassment or fear, and no recommendation from a health professional.

- Highly sensitive guaiac-based fecal occult blood test (gFOBT) every year*
- Highly sensitive fecal immunochemical test (FIT) every year*
- Multi-targeted stool DNA (MT-sDNA) test every 3 years*
- Colonoscopy every 10 years
- Flexible sigmoidoscopy every 5 years
- CT colonography (virtual colonoscopy) every 5 years *

*If any of these tests show a positive (suspicious) finding, a colonoscopy should be performed in order to complete the screening process.

American Cancer Society Cancer Action Network | 655 15th St. NW, Ste. 503 | Washington, DC 20005 | 🧕

The American Cancer Society colorectal cancer guidelines recommend one of the following stool or structural screening exams starting at age 45 for average risk individuals:

¹ American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.

² American Cancer Society. Colorectal Cancer Facts & Figures 2020-2022. Atlanta: American Cancer Society; 2020.

³ Meester, R. G., Doubeni, C. A., Lansdorp-Vogelaar, I., Goede, S. L., Levin, T. R., Quinn, V. P., Ballegooijen, M. v., Corley, D. A., & Zauber, A. G. (2015). Colorectal cancer deaths attributable to nonuse of screening in the United States. Annals of epidemiology, 25(3), 208–213.e1. <u>https://doi.org/10.1016/j.annepidem.2014.11.011</u>

[@]ACSCAN FB/ACSCAN | fightcancer.org ©2022, American CancerSociety Cancer Action Network, Inc.

Enabling all to achieve equal access to care could substantially reduce disparities in CRC

ACS CAN is fighting to achieve health equity, the just and fair opportunity for everyone to prevent, find, treat, and survive cancer - regardless of how much money they make, the color of their skin, their sexual orientation, their gender identity, their disability status, or where they live.

ACS CAN's Position

ACS CAN supports several initiatives aimed at reducing disparities in colorectal cancer incidence and mortality by increasing colorectal cancer screening rates, including:

- Appropriating funds to invest in state and federal colorectal cancer screening and control programs. Programs should raise public awareness about colorectal cancer screening and improve access to screening, including patient navigation and treatment services. Programs should use evidence-based patient and provider interventions to promote screening and reduce barriers to eligible adults.
- Ensure coverage without cost-sharing for colonoscopies after a positive stool screening exam as recommended by the American Cancer Society colorectal cancer guidelines.
- Ensure coverage of colorectal cancer screenings beginning at age 45, as recommended by the American Cancer Society colorectal cancer guidelines.
- Evidence-based educational efforts to improve uptake of preventive services, particularly culturally competent interventions tailored to specific populations.

Last Reviewed February 2022